Alzheimer's disease

Biogen halts Alzheimer's drug trials in 'transformative' failure for the biotech
BioPharma Dive
Thu, 03/21/19 - 09:56 am
Biogen
Eisai
Alzheimer's disease
clinical trials
aducanumab
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Endpoints
Tue, 03/19/19 - 10:30 am
Axovant
Alzheimer's disease
Roivant
Vivek Ramaswamy
Urovant
vibegron
urinary incontinence
IBM uses machine learning to detect early Alzheimer’s in blood samples
Fierce Biotech
Mon, 03/11/19 - 11:48 am
IBM
machine learning
artificial intelligence
Alzheimer's disease
diagnostics
40 Sites Across The Country To Test New Alzheimer's Drug
Forbes
Wed, 02/20/19 - 06:01 pm
clinical trials
Alzheimer's disease
troriluzole
Biohaven
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
Xconomy
Wed, 02/6/19 - 10:34 pm
Alector
IPOs
Alzheimer's disease
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test
Xconomy
Wed, 01/30/19 - 11:56 am
Roche
Alzheimer's disease
clinical trials
AC Immune
crenezumab
Biogen
aducanumab
Spinraza sales lift Biogen revenues
BioCentury
Tue, 01/29/19 - 11:15 pm
Biogen
earnings
aducanumab
Alzheimer's disease
Wren raises £18M to drug protein-misfolding diseases
Fierce Biotech
Tue, 01/22/19 - 11:44 am
Wren Therapeutics
protein-misfolding
Alzheimer's disease
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
Sun, 01/20/19 - 10:24 pm
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt
Endpoints
Thu, 01/17/19 - 09:42 am
Alzheon
IPOs
clinical trials
ALZ-801
Alzheimer's disease
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
BioSpace
Mon, 01/14/19 - 11:32 am
FDA
Amneal
generics
Novartis
Exelon Patch
Alzheimer's disease
Parkinson's Disease
The Anti-Alzheimer's BOLD Act Isn't. But It Could Be A Step In The Right Direction
Forbes
Thu, 01/10/19 - 12:12 am
Alzheimer's disease
BOLD Act
dementia
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs
Xconomy
Tue, 01/8/19 - 09:19 am
IPOs
Alector
Alzheimer's disease
dementia
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Mon, 01/7/19 - 11:20 am
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Fierce Biotech
Wed, 12/12/18 - 11:50 am
Eli Lilly
AC Immune
Alzheimer's disease
tau
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Pharmaceutical Business Review
Mon, 12/10/18 - 01:15 pm
Eisai
Alzheimer's disease
E2814
clinical trials
University College London
Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
Fierce Biotech
Mon, 12/3/18 - 10:46 pm
UCLA
Alzheimer's disease
dementia
drug discovery
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
CP Wire
Tue, 11/27/18 - 12:02 pm
biotech
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases

Pages